Professional
Added to YB: 2024-05-30
Pitch date: 2024-05-15
NTRA [bullish]
Natera, Inc.
+117.36%
current return
Author Info
No bio for this author
Company Info
Natera, Inc., a diagnostics company, provides molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Market Cap
$28.2B
Pitch Price
$106.71
Price Target
N/A
Dividend
N/A
EV/EBITDA
-91.38
P/E
-89.19
EV/Sales
12.92
Sector
Biotechnology
Category
growth
Parnassus Growth Equity Fund New Position: Natera, Inc.
NTRA: Genetic testing co. in women's health, oncology & organ transplant. Upside from wider test adoption, coverage expansion & new products. Strong mgmt to reach CF breakeven in '23 while balancing growth & profits.
Read full article (1 min)